Immunovant stockholders elect directors, ratify auditor, approve compensation at 2024 annual meeting

Immunovant, Inc.

Three directors (Salzmann, Migausky, Hughes) elected with over 97M votes for each, ~6.5M broker non-votes.
Ernst & Young ratified as auditor for FY ending March 31, 2025: 138,241,628 for, 16,740 against.
Non-binding advisory approval of named executive officer compensation: 128,494,310 for, 3,249,170 against.
Approximately 95% of eligible shares (138.3M) represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.